Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Korro Bio, Inc. (KRRO)
Company Research
Source: GlobeNewswire
—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration (FDA) Granted Orphan Drug Designation to KRRO-110 for the treatment of AATD —Executing 3-2-1 strategy through end of 2027 with the goal of establishing three clinical-stage development programs, targeting two tissue types with a single RNA-editing platform; Second development candidate expected to be announced in 2025 —Strengthened leadership team with the formation of Clinical Advisory Board and key additions to board and management team —Ended 2024 with a strong balance sheet of $163.1 million in
Read more
Impact Snapshot
Event Time:
KRRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRRO alerts
High impacting Korro Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRRO
News
- Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its price target lowered by analysts at Royal Bank of Canada from $105.00 to $95.00. They now have an "outperform" rating on the stock.MarketBeat
- Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? [Yahoo! Finance]Yahoo! Finance
- KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin DeficiencyGlobeNewswire
- Korro to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswire
KRRO
Earnings
- 11/12/24 - Beat
KRRO
Sec Filings
- 3/27/25 - Form 8-K
- 3/18/25 - Form S-8
- 3/18/25 - Form 10-K
- KRRO's page on the SEC website